Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended February 28, 2010
Business Overview: AngioDynamics designs, develops, manufactures, and markets medical devices for minimally invasive, image-guided procedures. The company operates three reportable segments: Peripheral Vascular, Access, and Oncology/Surgery. Key products include devices for treating peripheral vascular disease, vascular access, and oncology therapies such as radiofrequency ablation (RFA) and irreversible electroporation (IRE).
Key Financial Metrics
(All figures in thousands, except per share data)
| Metric | Three Months Ended Feb 28, 2010 | Nine Months Ended Feb 28, 2010 |
|---|---|---|
| Net Sales | $52,207 | $155,758 |
| Gross Profit | $30,273 (58.0% margin) | $92,012 (59.1% margin) |
| Operating Income | $5,593 (10.7% margin) | $14,488 (9.3% margin) |
| Net Income | $3,333 | $8,573 |
| Diluted EPS | $0.13 | $0.35 |
| Cash & Cash Equivalents | $37,513 | $37,513 (as of Feb 28, 2010) |
| Marketable Securities | $48,265 | $48,265 (as of Feb 28, 2010) |
| Total Debt | $6,870 (Current: $255; Long-term: $6,615) | $6,870 (as of Feb 28, 2010) |
| Operating Cash Flow (9mo) | N/A | $23,814 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% ($2.8M) for the quarter and 10% ($13.6M) for the nine-month period compared to the prior year. Growth was driven by increased unit sales of VenaCure EVLT kits, LC Beads, RF electrodes, NanoKnife IRE generators, and Benephit renal infusion products.
- Profitability: Operating income improved significantly, rising 113% for the quarter and 28% for the nine-month period. This was largely due to a $2.6M reduction in General and Administrative (G&A) expenses for the quarter, which excluded $2.8M in one-time CEO transition costs incurred in the prior year.
- Margins: Gross profit margins declined slightly (from 61.1% to 58.0% in the quarter) due to lower average selling prices in the Access segment and competitive pricing pressures on VenaCure kits, offset by higher material costs.
- Segment Performance:
- Peripheral Vascular: Sales up 8% (quarter) and 9% (nine months).
- Access: Sales down 6% (quarter) and flat (nine months) due to price declines and lower PICC sales.
- Oncology/Surgery: Sales up 19% (quarter) and 24% (nine months), driven by LC Beads and NanoKnife IRE.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenditures to remain between 8% and 10% of net sales in fiscal 2010 and 2011, primarily due to continued investment in IRE technology. The company believes current cash and investment balances ($85.8M total) are sufficient to meet capital needs for at least the next 12 months.
- Recent Developments:
- Completed the move of corporate headquarters to a new facility in Latham, NY in March 2010.
- Amended the distribution agreement for LC Beads with Biocompatibles UK Limited, extending rights through December 31, 2011.
- Risks and Contingencies:
- Healthcare Reform: The Patient Protection and Affordable Care Act (signed March 2010) introduces a 2.3% excise tax on medical device sales effective in 2013 and may impact reimbursement rates.
- Litigation: Pending patent infringement lawsuit against Vascular Solutions regarding varicose vein treatment patents. Also involved in disputes with biolitec regarding indemnification obligations.
- Liquidity Risk: The company holds $1.85 million in auction rate securities that have failed auctions; while issuers are current on payments, liquidity may be restricted.
Investor Verification Checklist
- LC Bead Distribution: Verify the status of the distribution agreement with Biocompatibles UK Limited, which expires December 31, 2011, as LC Beads represent approximately 9% of net sales.
- Healthcare Reform Impact: Assess the potential financial impact of the 2.3% medical device excise tax and reimbursement changes mandated by the 2010 healthcare legislation.
- Auction Rate Securities: Confirm the liquidity status and fair value of the $1.85 million investment in failed auction rate securities.
- Patent Litigation: Monitor the outcome of the patent reexamination and litigation against Vascular Solutions, which could affect the Peripheral Vascular segment.
- CEO Transition Costs: Note that the significant improvement in G&A expenses is partially due to the absence of one-time CEO transition costs in the current period compared to the prior year.